SCHEMBL6079367

SCHEMBL6079367

Cc1cc(NC(=O)NC2CCN(C(C)C(c3ccccc3)c3ccccc3)C2)c2ccccc2n1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
IGF1R P08069 3/20 0.44
ALDH1A1 P00352 1/20 0.43
RAB9A P51151 2/20 0.43
GALR3 O60755 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ADRA2A P08913 1/20 0.42
DRD2 P14416 1/20 0.42
SLC6A2 P23975 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
SLC6A4 P31645 1/20 0.42
TMEM97 Q5BJF2 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
UTS2R Q9UKP6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6079358 1.00 HTT (0.45) HTTMEN1KMT2AIGF1RALDH1A1
SCHEMBL6079355 1.00 HTT (0.45) HTTMEN1KMT2AIGF1RALDH1A1
SCHEMBL6079689 1.00 HTT (0.45) HTTMEN1KMT2AIGF1RALDH1A1
SCHEMBL6079685 1.00 HTT (0.45) HTTMEN1KMT2AIGF1RALDH1A1
SCHEMBL6079817 0.83 HTT (0.50) HTTMEN1KMT2AIGF1RALDH1A1
SCHEMBL6080227 0.83 HTT (0.50) HTTMEN1KMT2AIGF1RALDH1A1
SCHEMBL6079805 0.83 HTT (0.50) HTTMEN1KMT2AIGF1RALDH1A1
SCHEMBL6080077 0.82 SIGMAR1 (0.47) HTTMEN1KMT2AIGF1RALDH1A1
SCHEMBL6078927 0.81 UTS2R (0.48) HTTMEN1KMT2AIGF1RALDH1A1
SCHEMBL6079575 0.81 UTS2R (0.48) HTTMEN1KMT2AIGF1RALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060094716-A1 1-Pyridin-4-yl-urea derivatives ACTELION PHARMACEUTICALS LTD (CH) 2006-05-04 US claimed
EP-1554249-A2 1-PYRIDIN-4-YL-UREA DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2005-07-20 EP claimed
WO-2004026836-A2 1-PYRIDIN-4-YL-UREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2004-04-01 WO claimed
US-20060094716-A1 1-Pyridin-4-yl-urea derivatives ACTELION PHARMACEUTICALS LTD (CH) 2006-05-04 US disclosed
EP-1554249-A2 1-PYRIDIN-4-YL-UREA DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2005-07-20 EP disclosed
WO-2004026836-A2 1-PYRIDIN-4-YL-UREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094716-A1 1-Pyridin-4-yl-urea derivatives P2RY4, P2RX4, REN HTT 1465/4885MEN1 871/4885KMT2A 3136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.